---
title: "Cardiff Oncology Amends Onvansertib License, Resolves Litigation"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298934920.md"
description: "Cardiff Oncology and Nerviano Medical Sciences resolved litigation over their onvansertib license via a confidential settlement, dismissing the U.S. lawsuit with prejudice and exchanging mutual releases without monetary payments. They executed an amended license that tightens exclusivity, reshapes royalty structures, adds milestone obligations for Phase 3 trials, and grants Nerviano governance rights. Concurrently, analyst ratings remain mixed, with one Buy at $6.00 target and Spark AI labeling CRDF as Neutral due to weak financial performance."
datetime: "2026-09-14T13:47:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298934920.md)
  - [en](https://longbridge.com/en/news/298934920.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298934920.md)
generator: "portal-rs"
---

# Cardiff Oncology Amends Onvansertib License, Resolves Litigation

Cardiff Oncology ( (CRDF) ) has shared an announcement.

On September 14, 2026, Cardiff Oncology and Nerviano Medical Sciences agreed to a confidential settlement resolving litigation over inventorship and performance issues tied to their 2017 license for onvansertib, Cardiff’s lead PLK1 inhibitor. The parties will dismiss the U.S. lawsuit with prejudice, exchange mutual releases without any admission of liability or monetary payments, and solidify their ongoing collaboration around the global development and commercialization of onvansertib.

Concurrently, the companies executed an amendment to the license that tightens exclusivity on competing products, reshapes royalty and fee structures, and introduces new milestone and performance-related obligations linked to Cardiff’s planned Phase 3 program in first-line RAS-mutated metastatic colorectal cancer. The revised terms also give Nerviano governance rights, including a board observer and Scientific Advisory Board seat, and update post-termination, assignment and termination-for-cause provisions, clarifying economics and control as onvansertib progresses toward late-stage development. 

The most recent analyst rating on (CRDF) stock is a Buy  
 with a $6.00 price target.  
 To see the full list of analyst forecasts on Cardiff Oncology stock,  
 see the CRDF Stock Forecast page. 

**Spark’s Take on CRDF Stock**

According to Spark, TipRanks’ AI Analyst, CRDF is a Neutral.

Overall score is weighed down primarily by weak financial performance (large ongoing losses and sustained negative operating/free cash flow), with only partial offset from low debt levels. Technicals are mixed with modest near-term strength but a weaker longer-term trend. Valuation metrics are unfavorable/limited due to negative earnings and no dividend yield provided.

To see Spark’s full report on CRDF stock,  
 click here. 

**More about Cardiff Oncology**

Cardiff Oncology is a clinical-stage biotechnology company focused on developing innovative cancer therapies centered on PLK1 inhibition, a validated oncology target with potential to change treatment practice. Its lead asset, onvansertib, is an oral PLK1 inhibitor being advanced toward a registrational trial in first-line RAS‑mutated metastatic colorectal cancer and is also being studied in other PLK1‑driven tumors.

Nerviano Medical Sciences is a clinical-stage biopharmaceutical company specializing in oncology, combining a portfolio of small-molecule therapies, an antibody-drug conjugate platform and a discovery engine, with operations across Italy, the U.S., China and Hong Kong. 

**Average Trading Volume:** 1,204,383

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $94.13M

For a thorough assessment of CRDF stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [CRDF.US](https://longbridge.com/en/quote/CRDF.US.md)

## Related News & Research

- [Cardiff Oncology Participates in UBS Global Biopharma Conference](https://longbridge.com/en/news/304109998.md)
- [Cardiff Oncology, Nerviano Medical Sciences expand onvansertib collaboration under amended license agreement](https://longbridge.com/en/news/298926023.md)
- [LUNR: Revenue topped $269M as backlog hit $1.9B; FY26 revenue guidance is $920M-$950M](https://longbridge.com/en/news/305314600.md)
- [Nvidia options traders bank on longer-term stock recovery](https://longbridge.com/en/news/305359219.md)
- [The S&P 500 is shrugging off Nvidia's selloff. Here's what's keeping the rest of the market afloat.](https://longbridge.com/en/news/305355417.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**